In order to get an overview of the extent of SRGN expression in various cancers and compare it to GBM patients, we analyzed a large set of publicly available expression data in the R2 analysis webtool (R2 Genomics and Visualization Platform, Oncogenomics, AMC) to explore the landscape of SRGN expression patterns across major human cancers (prostate, ovary, lung, kidney, endometrium, colon, breast, myeloma, hepatocellular carcinoma (HCC), glioblastoma (GBM), non-small cell lung carcinoma (NSCLC), medulloblastoma (MB), B-cell lymphoma). Here, SRGN is linked to hepatocellular carcinoma.